About Kallistatin
Kallistatin (SERPINA4) is a protein
from Homo sapiens identified by UniProt accession
P29622, 427 residues long.
MolForge cross-references it against 0 known binders and
177 disease associations.
Target properties
| Protein name | Kallistatin |
|---|
| UniProt accession | P29622 |
|---|
| Gene | SERPINA4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 427 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (177)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.39
- kallistatin measurement · score 0.31
- protein measurement · score 0.26
- serum albumin measurement · score 0.26
- breast adenocarcinoma · score 0.25
- sex hormone-binding globulin measurement · score 0.21
- vaspin measurement · score 0.18
- diabetes mellitus · score 0.09
- non-alcoholic fatty liver disease · score 0.08
- liver dysplastic nodule · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P29622-F1 | alphafold | PREDICTED | 86.67 | — |
Amino-acid sequence (427 residues)
MHLIDYLLLL LVGLLALSHG QLHVEHDGES CSNSSHQQIL ETGEGSPSLK IAPANADFAF RFYYLIASET PGKNIFFSPL SISAAYAMLS LGACSHSRSQ ILEGLGFNLT ELSESDVHRG FQHLLHTLNL PGHGLETRVG SALFLSHNLK FLAKFLNDTM AVYEAKLFHT NFYDTVGTIQ LINDHVKKET RGKIVDLVSE LKKDVLMVLV NYIYFKALWE KPFISSRTTP KDFYVDENTT VRVPMMLQDQ EHHWYLHDRY LPCSVLRMDY KGDATVFFIL PNQGKMREIE EVLTPEMLMR WNNLLRKRNF YKKLELHLPK FSISGSYVLD QILPRLGFTD LFSKWADLSG ITKQQKLEAS KSFHKATLDV DEAGTEAAAA TSFAIKFFSA QTNRHILRFN RPFLVVIFST STQSVLFLGK VVDPTKP
Explore Kallistatin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets